Paloma Partners’s Insys Therapeutics, Inc. INSY Stock Holding History

Paloma Partners’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-27,106	Closed	-$249K	–	2368
2016 Q4	$249K	Buy	+27,106	New	+$306K	﹤0.01%	1766

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCP

Fine Capital Partners New York $563M AUM 7.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Paloma Partners's INSY Position: Q1 2017 in Review

Paloma Partners sold out of Insys Therapeutics, Inc. (INSY) in Q1 2017, closing a stake of 27,106 shares — an estimated $249K sold.

Paloma Partners first reported a position in INSY in Q4 2016 and held it in 1 quarter. The position peaked at $249K in Q4 2016. 116 funds tracked by Wall St. Rank hold INSY as of Q1 2017.

Paloma Partners reported no remaining Insys Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Paloma Partners sold 27,106 Insys Therapeutics, Inc. shares in Q1 2017, an estimated $249K.
Paloma Partners first reported a position in Insys Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
Paloma Partners's Insys Therapeutics, Inc. position peaked at $249K in Q4 2016.
116 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2017.

Based on Paloma Partners's 13F filing for Q1 2017, filed 15 May 2017.